A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 alone and with MVA RH5

Objectives

This is the first study to test two candidate malaria vaccines in humans. The specific objectives are:

1. To assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination.

2. To assess the safety of the vaccines and the extent of the immune response in healthy volunteers.